Supplemental Table 1-3 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion

Supplemental table 1 and 2 is the clinical characteristics of patients analyzed in figure 1B. Supplemental table 3 is the GR50 of breast cancer cell lines treated with Doxorubicin with the addition of either Maraviroc or Vicriviroc.